Combination immunotherapy with prostate GVAX and ipilimumab: Safety and toxicity

Immunotherapy

Volumn 4, Issue 6, 2012, Pages 577-580

  Karan, Dev ^a,b   Van Veldhuizen, Peter ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cellular vaccine; GVAX; immunotherapy; ipilimumab; prostate

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA DR ANTIGEN; HYDROCORTISONE; IPILIMUMAB; LEVOTHYROXINE; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANTIBODY RESPONSE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOREACTIVITY; LUNG ALVEOLITIS; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 84863914828     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.53     Document Type: Note

References (18)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011
2. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N. Engl. J. Med. 364, 2055-2058 (2011
3. Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-Treated castration-Resistant prostate cancer. J. Clin. Oncol. 28, 1496-1501 (2010
4. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011
5. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011
6. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-Resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010
7. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010
8. Small EJ, Tchekmedyian NS, Rini BI et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-Refractory prostate cancer. Clin. Cancer Res. 13, 1810-1815 (2007
9. Van Den Eertwegh AJ, Versluis J, Van Den Berg HP et al. Combined immunotherapy with granulocyte-macrophage colony-Stimulating factor-Transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-Resistant prostate cancer: A Phase 1 dose-Escalation trial. Lancet Oncol. 13(5), 509-517 (2012
10. Simons JW, Carducci MA, Mikhak B et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin. Cancer Res. 12, 3394-3401 (2006
11. Chen H, Liakou CI, Kamat A et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-Gamma levels in both nonmalignant and malignant prostate tissues. Proc. Natl Acad. Sci. USA 106, 2729-2734 (2009
12. Qureshi OS, Zheng Y, Nakamura K et al. Trans-Endocytosis of CD80 and CD86: A molecular basis for the cell-Extrinsic function of CTLA-4. Science 332(6029), 600-603 (2011
13. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175, 7746-7754 (2005
14. Fong L, Kwek SS, O'Brien S et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 69, 609-615 (2009
15. Madan RA, Mohebtash M, Arlen PM et al. Ipilimumab and a poxviral vaccine targeting prostate-Specific antigen in metastatic castration-Resistant prostate cancer: A Phase 1 dose-Escalation trial. Lancet Oncol. 13(5), 501-508 (2012
16. Ganesh BB, Cheatem DM, Sheng JR et al. GM-CSF-Induced CD11c+CD8a - dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis. Int. Immunol. 21, 269-282 (2009
17. Flohe S, Lendemans S, Selbach C et al. Effect of granulocyte-macrophage colony-Stimulating factor on the immune response of circulating monocytes after severe trauma. Crit. Care Med. 31, 2462-2469 (2003
18. Perry SE, Mostafa SM, Wenstone R et al. HLA-DR regulation and the influence of GM-CSF on transcription, surface expression and shedding. Int. J. Med. Sci. 1, 126-136 (2004)